Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106; and Evotec AG for the novel target for fibrosis and other indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone321-534-2900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$375.38 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date4/25/2019 (Confirmed)
OptionableOptionable
GALAPAGOS NV/S (NASDAQ:GLPG) Frequently Asked Questions
What is GALAPAGOS NV/S's stock symbol?
GALAPAGOS NV/S trades on the NASDAQ under the ticker symbol "GLPG."
When is GALAPAGOS NV/S's next earnings date?
What price target have analysts set for GLPG?
14 equities research analysts have issued 12-month price targets for GALAPAGOS NV/S's shares. Their forecasts range from $90.00 to $157.00. On average, they anticipate GALAPAGOS NV/S's share price to reach $127.3636 in the next year. This suggests a possible upside of 13.7% from the stock's current price. View Analyst Price Targets for GALAPAGOS NV/S.
What is the consensus analysts' recommendation for GALAPAGOS NV/S?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GALAPAGOS NV/S in the last year. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GALAPAGOS NV/S.
What are Wall Street analysts saying about GALAPAGOS NV/S stock?
Here are some recent quotes from research analysts about GALAPAGOS NV/S stock:
- 1. Cantor Fitzgerald analysts commented, ". Reiterate Overweight and PT of $130. Phase 3 filgotinib data exceeded our expectations supporting a potentially best in class JAK. Galapagos and Gilead (OW, Young) reported the remaining two Ph3 studies in the FINCH program for RA. What we found most compelling in this dataset is differentiated safety compared to other JAK inhibitors on both rates of thrombotic events as well as infections. Although expectations were high heading into this readout for GLPG, we think that shares could trade up 10-15% as we see differentiated safety from key competitor AbbVie’s (NC) upadacitnib." (3/26/2019)
- 2. According to Zacks Investment Research, "Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. " (3/1/2019)
Has GALAPAGOS NV/S been receiving favorable news coverage?
News articles about GLPG stock have been trending somewhat positive on Wednesday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. GALAPAGOS NV/S earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term.
Who are some of GALAPAGOS NV/S's key competitors?
Some companies that are related to GALAPAGOS NV/S include Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY), Marina Biotech (MRNA), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Jazz Pharmaceuticals (JAZZ) and Beigene (BGNE).
What other stocks do shareholders of GALAPAGOS NV/S own?
Who are GALAPAGOS NV/S's key executives?
GALAPAGOS NV/S's management team includes the folowing people:
- Mr. Onno van de Stolpe, Co-Founder, MD, CEO & Exec. Director (Age 60)
- Mr. Bart Filius MBA, CFO & COO (Age 49)
- Dr. Piet Wigerinck, Chief Scientific Officer (Age 55)
- Ms. Elizabeth Goodwin, VP of Investor Relations & Corp. Communications
- Dr. Andre Hoekema, Chief Bus. Officer (Age 62)
When did GALAPAGOS NV/S IPO?
(GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at a price of $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.
Who are GALAPAGOS NV/S's major shareholders?
GALAPAGOS NV/S's stock is owned by a number of of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (0.17%), Dorsey Wright & Associates (0.09%), Eqis Capital Management Inc. (0.05%), Henry James International Management Inc. (0.04%) and Financial Gravity Wealth Inc. (0.01%).
Which major investors are selling GALAPAGOS NV/S stock?
GLPG stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC.
Which major investors are buying GALAPAGOS NV/S stock?
GLPG stock was acquired by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc., Financial Gravity Wealth Inc., Henry James International Management Inc. and Dorsey Wright & Associates.
How do I buy shares of GALAPAGOS NV/S?
Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GALAPAGOS NV/S's stock price today?
One share of GLPG stock can currently be purchased for approximately $112.05.
How big of a company is GALAPAGOS NV/S?
GALAPAGOS NV/S has a market capitalization of $5.74 billion and generates $375.38 million in revenue each year. The biotechnology company earns $-34,560,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis.
What is GALAPAGOS NV/S's official website?
How can I contact GALAPAGOS NV/S?
GALAPAGOS NV/S's mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected]
MarketBeat Community Rating for GALAPAGOS NV/S (NASDAQ GLPG)
MarketBeat's community ratings are surveys of what our community members think about GALAPAGOS NV/S and other stocks. Vote "Outperform" if you believe GLPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLPG will underperform the S&P 500 over the long term. You may vote once every thirty days.
